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Li-Fraumeni syndrome (LFS) patients harbor germ linemuta-
tions in the TP53 gene and are at increased risk of hormone
receptor-positive breast cancers. Recently, elevated levels of
aromatase, the rate-limiting enzyme for estrogen biosynthesis,
were found in the breast tissue of LFS patients. Although p53
down-regulates aromatase expression, the underlying mecha-
nisms are incompletely understood. In the present study, we
found that LFS stromal cells expressed higher levels of Hsp90
ATPase activity and aromatase compared with wild-type stro-
mal cells. Inhibition of Hsp90 ATPase suppressed aromatase
expression. Silencing Aha1 (activator of Hsp90 ATPase 1), a co-
chaperone of Hsp90 required for its ATPase activity, led to both
inhibition of Hsp90 ATPase activity and reduced aromatase
expression. In comparison with wild-type stromal cells, in-
creased levels of the Hsp90 client proteins, HIF-1, and PKM2
were found in LFS stromal cells. A complex comprised of
HIF-1 and PKM2 was recruited to the aromatase promoter II
in LFS stromal cells. Silencing either HIF-1 or PKM2 sup-
pressed aromatase expression in LFS stromal cells. CP-31398,
a p53 rescue compound, suppressed levels of Aha1, Hsp90
ATPase activity, levels of PKM2 and HIF-1, and aromatase
expression in LFS stromal cells. Consistent with these in vitro
findings, levels of Hsp90ATPase activity, Aha1, HIF-1, PKM2,
and aromatase were increased in the mammary glands of p53
null versus wild-type mice. PKM2 and HIF-1 were shown to
co-localize in the nucleus of stromal cells of LFS breast tissue.
Taken together, our results show that the Aha1-Hsp90-PKM2/
HIF-1 axis mediates the induction of aromatase in LFS.
Estrogen is an important mediator in the development and
progression of breast cancer. Cytochrome P450 aromatase, a
product of the CYP19A1 gene, catalyzes the synthesis of estro-
gens from androgens (1). In postmenopausal women, the adi-
pose tissue becomes themain site of estrogen biosynthesis, and
particularly, the breast adipose tissue is considered an impor-
tant source of estrogens that drive the growth of hormone-de-
pendent breast cancers. Consequently, it is important to eluci-
date the mechanisms that regulate the transcription of the
CYP19A1 gene. The expression of aromatase is tightly regu-
lated, with transcription being under the control of several dis-
tinct tissue-selective promoters (2–4). In normal breast adi-
pose tissue, aromatase is expressed at low levels under the
control of promoter I.4, whereas in obesity and cancer, the
coordinated activation of the proximal promoters I.3 and pro-
moter II (PII)3 causes a significant increase in aromatase
expression (3–5). The proximal promoters I.3 and PII are
located close to each other, activated by stimulation of the
cAMP 3 PKA 3 cAMP response element-binding protein
(CREB) pathway (6, 7), and aided by many other regulators
including CREB-regulated transcription co-activator 2
(CRTC2), p300, and hypoxia-inducible factor-1 (HIF-1)
(8–11).
Several cytokines and tumor promoters, including prosta-
glandin E2, tumor necrosis factor-, and interleukin-1 stimu-
late aromatase expression (4, 12). In addition, its expression is
regulated by oncogenes such asHER-2/neu and tumor suppres-
sor genes including BRCA1, LKB1, and p53 (9, 11, 13–18).
Germ linemutations in theTP53 gene, which encodes p53, lead
to Li-Fraumeni Syndrome (LFS). Among women with LFS, the
most common cancer is breast cancer, with the majority of
breast cancers being hormone receptor-positive (19, 20). Aro-
matase expression has been shown to be increased in breast
adipose stromal cells from LFS patients compared with non-
LFS breast tissue (16). Recently, we showed that epithelial cells
from LFS patients contained increased Hsp90 ATPase activity
because of the increased expression of Aha1, a co-chaperone of
Hsp90 (21, 22). Here, we extended these studies to breast adi-
pose stromal cells and show that aromatase expression is
increased in LFS versus wild-type stromal cells and that this
increase is dependent on Hsp90 ATPase signaling involving
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Aha1, HIF-1, and PKM2. Consistent with these in vitro find-
ings, levels of aromatasewere increased in themammary glands
of p53 null versus wild-type mice. Taken together, this study
provides new insights into the mechanism by which p53 regu-
lates aromatase expression in stromal cells, which may be
important for understanding the pathogenesis of estrogen-de-
pendent breast cancer.
Results
Regulation of Aromatase by p53 Is Dependent on Hsp90—
Initially, we compared levels of aromatase in stromal cells that
were wild-type for p53 versus stromal cells from a LFS patient
that expressed mutant p53. As shown in Fig. 1 (A and B), levels
of aromatasemRNA, protein, and activity were increased in the
stromal cells derived from the LFS patient. Previously, we
reported thatmutant p53 led to increasedHsp90ATPase activ-
ity in epithelial cells (21, 22). Consistent with this prior finding,
Hsp90 ATPase activity was increased in LFS versus wild-type
stromal cells (Fig. 1C). To determine whether the elevated level
of Hsp90 ATPase activity was causally linked to the increased
levels of aromatase in LFS stromal cells, two inhibitors ofHsp90
ATPasewere used. Both 17-AAGandPU-H71 caused the dose-
dependent suppression of Hsp90 ATPase activity and aroma-
FIGURE 1.Hsp90 is important for the p53-mediated increase in aromatase levels in LFS stromal cells.A–C, WT and LFS stromal cells were used. InD–I, LFS
cells were treated with the indicated concentrations of 17-AAG (D–F) or PU-H71 (G–I) for 24 h. In A, F, and I, aromatase activity was measured. In B, E, and H,
aromatasemRNA levelsweremeasured. InC,D, andG, Hsp90ATPase activitywasmeasured.A–I, means S.D. (error bars) are shown,n 6. **,p 0.01; ***p
0.001 compared with wild-type stromal cells (A–C) and in D–I, compared with vehicle-treated cells.
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tase in LFS stromal cells (Fig. 1,D–I). To further interrogate the
role of p53 in regulating aromatase levels, CP-31398, a p53
rescue compound was used (23). LFS stromal cells were
transfected with a p53-luciferase construct. Treatment with
CP-31398 caused the dose-dependent induction of p53-lucifer-
ase activity (Fig. 2A) without affecting p53 protein levels (Fig.
2A, inset). The same dose range of CP-31398 suppressedHsp90
ATPase activity and down-regulated aromatase expression and
activity (Fig. 2, B–D). Next, we determined the effects of silenc-
ing p53 on Hsp90 ATPase activity and aromatase expression in
wild-type stromal cells. As shown in Fig. 3 (A–C), silencing of
p53 led to increased Hsp90 ATPase activity and an associated
increase in aromatase levels and activity. Silencing p53 with a
different set of siRNAs also induced aromatase (data not
shown). Similar inductive effects were observed in primary
human adipose stromal cells (data not shown). Next we com-
pared Hsp90 ATPase activity and aromatase levels in HCT116
cells that were wild-type or null for p53. Levels of Hsp90
ATPase activity and aromatase mRNA were increased in the
HCT116 p53 null cell line (Fig. 3, D and E). To further investi-
gate this relationship, we employed a p53 null cell line (EB-1) in
which p53 is induced by exogenous ZnCl2 (24, 25). Transient
transfections were carried out to establish the concentration
range of ZnCl2 that stimulated p53-luciferase activity. Treat-
ment with 0–100 M ZnCl2 led to a dose-dependent induction
of p53-luciferase activity and p53 protein levels (Fig. 3F). The
same concentration range of ZnCl2 down-regulated Hsp90
ATPase activity and aromatase levels (Fig. 3, G and H). Previ-
ously, we demonstrated in epithelial cells that p53 suppresses
Aha1, a co-chaperone of Hsp90, leading to inhibition of Hsp90
ATPase activity (21). Accordingly, we next determinedwhether
this mechanism was operative in stromal cells and important
for the regulation of aromatase expression. Levels of Aha1
were increased in LFS versus wild-type stromal cells (Fig. 4A).
Silencing of p53 in a wild-type stromal cell line (Fig. 4B) or
primary human adipose stromal cells (data not shown) induced
Aha1 protein expression. Similar effects were found using a
second set of siRNAs to p53 (data not shown). Similarly, levels
of Aha1were higher inHCT116 cells thatwere null for p53 (Fig.
4B). Treatment of LFS cells with CP-31398 caused the dose-de-
pendent suppression of Aha1 levels (Fig. 4C). Consistent with
the known function of Aha1, silencing of Aha1 down-regulated
Hsp90 ATPase activity in LFS stromal cells (Fig. 4D). Impor-
tantly, silencing of Aha1 led to reduced aromatase expression
and activity in these cells (Fig. 4, E and F).
p53 Regulates Hsp90 ATPase Activity Leading to the Stabili-
zation of HIF-1 and PKM2—HIF-1 is a client protein of
Hsp90 and a known regulator of aromatase expression (26–28).
FIGURE 2.Reactivationof p53 leads to inhibitionof aromatase activity in LFS stromal cells. InA–D, LFS stromal cellswere used. InA, LFS stromal cellswere
transfectedwith 1.8gofp53-luciferase construct and0.2gofpsv--galactosidase construct. 24h after transfection, the cellswere treatedwith the indicated
concentrations of CP-31398. 24 h later, the cells were harvested, and luciferase activity was measured. Luciferase activity was normalized to -galactosidase
activity. Inset, LFS cellswere also treatedwith the indicated concentrations of CP-31398, lysateswere subjected toWestern blotting, and theblotswere probed
as indicated. In B–D, the cells were treatedwith the indicated concentrations of CP-31398 for 24 h. In B, Hsp90 ATPase activity wasmeasured. In C andD, levels
of aromatasemRNAand activityweremeasured in cell lysates.A–D, means S.D. (error bars) are shown,n 6. *, p 0.05; **, p 0.01; ***, p 0.001 compared
with vehicle-treated cells.
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PKM2 is a co-activator of HIF-1-mediated gene expression
(29–32). Hence, we investigated whether these two proteins
could be important for mediating the effects of p53 on aroma-
tase. Levels ofHIF-1 and PKM2were increased in LFS stromal
cells (Fig. 5A, left panel). Levels of PKM2 and HIF-1were also
increased in p53 null versus wild-type HCT116 cells (Fig. 5A,
right panel). Next, we investigated whether HIF-1 and PKM2
were in a complexwithHsp90. In LFS comparedwithwild-type
stromal cells, therewasmoreHIF-1 and PKM2 that co-immu-
noprecipitated with Hsp90 (Fig. 5B). Treatment of LFS stromal
cells with CP-31398 led to a loss of HIF-1, PKM2, and Hsp90
complexes (Fig. 5C). In contrast, silencing of p53 in a wild-type
stromal cell line increased levels of HIF-1 and PKM2 and
stimulated the interaction between HIF-1, PKM2, and Hsp90
(Fig. 5D). Increased levels ofHIF-1 and PKM2were also found
in primary human adipose stromal cells in which p53 was
silenced (data not shown). To assess the role of Hsp90 ATPase
activity in regulating levels of these client proteins, 17-AAGand
FIGURE 3. p53 regulates Hsp90 ATPase activity and aromatase expression. In A–C, wild-type stromal cells were transfected with 2 g of siRNA to GFP
(control siRNA) or p53. 48 h after transfection, the cells were harvested, and levels of Hsp90 ATPase activity (A), aromatasemRNA (B), and aromatase activity (C)
weremeasured. InD and E, HCT116 cells wild-type or null for p53were used. The cells were harvested andHsp90ATPase activity (D) and aromatase expression
(E) were measured. In F–H, EB-1 cells were used. In F, the cells were transfected with 1.8 g of p53-luciferase construct and 0.2 g of psv--galactosidase
construct for 24 h. In F–H, EB-1 cells were treated with the indicated concentrations of ZnCl2 for 24 h. Inset, EB-1 cells were treated with the indicated
concentrations of ZnCl2 for 24 h, and the lysates were subjected to Western blotting. In F, the cells were harvested, and luciferase activity was measured.
Luciferase activity was normalized to -galactosidase activity. In G and H, levels of Hsp90 ATPase activity and aromatase mRNA levels were measured,
respectively. InA–H,meansS.D. (error bars) are shown,n6. *,p0.05; **,p0.01; ***,p0.001 comparedwith control siRNA-treated cells (A–C),wild-type
cells (D and E), or vehicle-treated cells (F–H).
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PU-H71 were used. Both of these inhibitors caused the dose-
dependent suppression of HIF-1 and PKM2 protein in LFS
stromal cells (Fig. 5, E and F). By contrast, treatment with
17-AAG did not affect PKM2 mRNA levels (data not shown).
Similar effectswere observedwhenAha1was silenced (Fig. 5G).
To evaluate whether p53 regulated this process, the effect of
CP-31398 on levels of Aha1, HIF-1, and PKM2 was deter-
mined. Treatment of LFS stromal cells with this p53 rescue
compound suppressed levels of each of these proteins (Fig. 5H).
Similarly, ZnCl2-mediated induction of p53 led to down-regu-
lation of Aha1, HIF-1 and PKM2 (Fig. 5I). Next, we explored
the significance of HIF-1 and PKM2 in regulating aromatase
expression. Because levels of HIF-1 and PKM2 (Fig. 5A), as
well as aromatase (Fig. 1, A and B), were increased in LFS
versuswild-type stromal cells, we investigated whether these
differences were causally linked. Initially, we explored the
possibility that HIF-1 and PKM2 were in a complex. As
shown in Fig. 6A, immunoprecipitating PKM2 led to co-pre-
cipitation of HIF-1 and vice versa in LFS stromal cells.
Next, we used cell fractionation to determine whether
HIF-1 and PKM2 were detectable in the nucleus in LFS
cells. As shown in Fig. 6B, both HIF-1 and PKM2 were
detectable in the nucleus of LFS cells with protein levels
being higher in LFS compared with wild-type cells. Similar
results were obtained when p53 was silenced in wild-type
cells (data not shown). To determine whether HIF-1 and
PKM2 bound to the CYP19A1 promoter, ChIP assays were
performed. ChIP assays revealed increased binding of both
HIF-1 (Fig. 6C) and PKM2 (Fig. 6D) to the proximal pro-
moter region of CYP19A1. Consistent with this binding
being functionally important, silencing of either HIF-1
(Fig. 6, E–G) or PKM2 (Fig. 6, H–J) in LFS stromal cells
suppressed aromatase promoter activity, expression, and
enzyme activity. Using a second set of siRNAs to PKM2 and
HIF-1, similar results were obtained (data not shown).
Levels of Hsp90 ATPase Activity, Aha1, HIF-1, PKM2, and
Aromatase Are Increased in p53 Null Mice—To assess the
impact of p53 on the Hsp90-aromatase axis in vivo, we utilized
FIGURE 4.Aha1 is important for p53-mediated regulation of aromatase in LFS stromal cells.A, levels of Aha1 and-actin inWT and LFS stromal cells were
determined in cell lysates by immunoblotting. In B (left panel) andD–F, cells were transfectedwith 2g of siRNA to GFP (control siRNA), p53 (B), or Aha1 (D–F).
48 h after transfection, the cellswere harvested, and levels of Aha1protein (B, left panel; and inset inD), Hsp90ATPase activity (D), and aromatasemRNA (E), and
aromatase activity (F) weremeasured. InB (right panel), lysateswereprepared fromp53wild-type andp53null HCT116 cells and subjected toWesternblotting.
In C, LFS cells were treatedwith the indicated concentrations of CP-31398 for 24 h. The cell lysates were prepared and subjected toWestern blotting. The blots
were probed as indicated. In D–F, means S.D. (error bars) are shown, n 6. ***, p 0.001 compared with cells transfected with GFP siRNA.
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mammary gland tissue from wild-type and p53 null mice. p53
protein was not detected in the mammary glands of p53 null
mice (Fig. 7A). Similar levels of Hsp90 were found in p53/
and p53/mice (Fig. 7A). Comparedwith wild-typemice, p53
null mice exhibited increased levels of Aha1, Hsp90 ATPase
activity, and HIF-1 and PKM2 protein levels (Fig. 7, B and C).
Moreover, levels of aromatase mRNA and activity were both
elevated in mammary glands from p53 null versus wild-type
mice (Fig. 7, D and E).
PKM2 IsDetectable in theNucleus of LFS Stromal Cells and Is
Positively Correlated with HIF-1 and Aromatase—The sub-
cellular localization of PKM2 was examined in adipose stro-
mal cells from LFS patients and compared with normal
breast tissue using immunofluorescence and confocal
microscopy. In normal breast tissue and consistent with in
vitro findings (Fig. 6B), PKM2 was observed in the cytoplasm
(Fig. 8A), whereas immunoreactivity for PKM2 was detecta-
ble in the nucleus of LFS stromal cells (Figs. 6B and 8B).
FIGURE 5.HIF-1 and PKM2 are client proteins of Hsp90. A, cell lysates fromwild-type and LFS stromal cells (left panel) and HCT116 cells (right panel) were
subjected to Western blotting, and the blots were probed as indicated. In B–D, immunoprecipitation experiments were performed. In B, cell lysates were
prepared from wild-type and LFS stromal cells; in C, LFS stromal cells were treated with 20 M CP-31398 for 3 h, and cell lysates were prepared; and in D,
wild-type cells were transfected with 2 g of siRNA to GFP (control siRNA) or p53. 48 h after transfection, the cells were harvested. In B–D, Hsp90 was
immunoprecipitatedwith control IgG or antibody to Hsp90. Immunoprecipitates were subjected toWestern blotting, and the blots were probed as indicated.
Blank, total cell lysateswere subjected toWestern blotting andprobed as indicated. In E and F, LFS stromal cellswere treatedwith the indicated concentrations
of 17-AAG and PU-H71 for 24 h. In G, LFS stromal cells were transfected with 2 g of siRNA to GFP (control siRNA) or Aha1. 48 h after transfection, cells were
harvested, and lysateswere prepared. InH, LFS cells were treatedwith the indicated concentrations of CP-31398 for 24 h. The cells were harvested, and lysates
were prepared. In I, EB-1 cells were treated with the indicated concentrations of ZnCl2 for 24 h, and cell lysates were prepared. In E–I, the cell lysates were
subjected to Western blotting, and the blots were probed with the indicated antibodies.
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HIF-1 and PKM2 also co-localized in the nucleus of LFS
breast adipose stromal cells (Fig. 8C), and a significant pos-
itive correlation between HIF-1 and PKM2 immunofluo-
rescence intensity was found following quantification of cell-
specific signals (Fig. 8D). Aromatase immunoreactivity was also
detected in cells with nuclear PKM2 (Fig. 8E) and positively
correlated with nuclear PKM2 (Fig. 8F) in LFS stromal cells. No
staining was detected when primary antibodies were omitted
(data not shown).
Discussion
The majority of LFS patients carry germ line mutations in
TP53, the gene that encodes p53, with affected individuals hav-
ing an increased risk of hormone receptor-positive breast can-
cer (16, 19, 20). This suggests an important causal role for p53
inactivation in breast carcinogenesis. Recently, p53 was found
to down-regulate aromatase expression (16). Consistent with
this finding, aromatase expression was increased in breast adi-
FIGURE 6.HIF-1 and PKM2 are important for the p53-mediated regulation of aromatase. In A, cell lysates prepared fromWT and LFS stromal cells were
either subjected toWestern blotting (Blank) or immunoprecipitatedwith control IgG, antibody to PKM2, or antibody to HIF-1 and then subjected toWestern
blotting. In B, lysates were prepared fromwild-type and LFS cells. Cytosolic and nuclear fractions were isolated, and 75g of total protein and equal volumes
of cytosolic and nuclear proteins were subjected to Western blotting, and the blots were probed as indicated. In C and D, ChIP assays were performed.
Chromatin fragments were immunoprecipitated with antibodies against HIF-1 (C) or PKM2 (D), and the aromatase promoter was amplified by real time PCR.
DNA sequencingwas carried out, and the PCR products were confirmed to be the aromatase promoter. This promoter was not detectedwhen normal IgGwas
used or when antibody was omitted from the immunoprecipitation step. In E and H, LFS stromal cells were transfected with 0.9 g of aromatase promoter
construct and 0.2 g of psv-gal constructs. 24 h later, the cells also received either 0.9 g of control siRNA, HIF-1 siRNA (E), or PKM2 siRNA (H). 48 h after
transfection, the cells were harvested, and luciferase activity was measured. Luciferase activity was normalized to -galactosidase activity. In F, G, I, and J, LFS
stromal cells were transfected with 2g of GFP siRNA (control), siRNA to HIF-1 (F and G), or siRNA to PKM2 (I and J). In F and I, 48 h after transfection, the cell
lysateswere subjected toWestern blotting (insets), and the blots were probed as indicated. In F and I, total RNAwas isolated, and aromatasemRNA levels were
measured. In G and J, aromatase activity was measured in cell lysates. In C–J, means S.D. (error bars) are shown, n 6. **, p 0.01; ***, p 0.001 compared
with wild-type cells (C and D); cells that were transfected with GFP siRNA (E–J).
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pose stromal cells from LFS compared with non-LFS patients.
However, the complex molecular mechanisms underlying the
effect of p53 on aromatase expression are poorly understood. In
the present study, we have not only confirmed previous results
demonstrating that p53 inhibits aromatase expression (16, 17)
but also have identified a novelmechanismbywhich this occurs
in LFS stromal cells. Importantly, we show that wild-type p53
suppresses Aha1 levels leading to inhibition of Hsp90 ATPase
activity. This results in reduced amounts of the Hsp90 client
proteins HIF-1 and PKM2 and suppression of aromatase lev-
els (Fig. 9).
Our data demonstrate that Hsp90 plays a significant role in
stimulating aromatase expression in LFS-derived stromal cells.
Previously, we showed that loss of p53 led to the induction of
Aha1, whichwas critical for increasedHsp90ATPase activity in
colon cancer cells (21, 22). In the current study, we demonstrate
that silencing of Aha1 leads to the suppression of Hsp90
ATPase activity, as well as aromatase expression in LFS-derived
stromal cells. Taken together, these results show for the first
time that p53 regulates aromatase expression in an Hsp90-de-
pendent fashion. Additionally, we show that Hsp90 ATPase
activity is increased in LFS-derived stromal cells, suggesting the
potential use of Hsp90 ATPase inhibitors for the prevention or
treatment of breast cancer in LFS patients. Previously, we
reported that HDAC6 functions as an Hsp90 deacetylase and
that inhibition of HDAC6 leads to Hsp90 hyperacetylation, its
dissociation from p23, a co-chaperone, and a loss of chaperone
activity (33). Inhibition of HDAC6 has been reported to down-
regulate aromatase expression (34), suggesting a possible role
for reduced Hsp90 ATPase in mediating this effect. Based on
the current results, future studies are warranted to test this
possibility.
HIF-1, a client protein of Hsp90 (26), has been shown to
stimulate aromatase in human breast adipose stromal cells (10).
Here, we show that increased Hsp90 ATPase activity found in
LFS-derived stromal cells leads to enhanced HIF-1 levels, the
increased binding of HIF-1 to the proximal promoter of
CYP19A1 (PII promoter), and a consequent increase in aroma-
tase expression. This is consistent with previous findings dem-
onstrating that HIF-1 binds to aromatase PII and is required
FIGURE7.Levelsof aromataseare increased inmammaryglandsofp53nullmice.Mammarygland tissue from femalep53wild-type andp53nullmicewas
used. A, lysates were subjected to Western blotting and probed as indicated. B, tissue lysates were used to measure Hsp90 ATPase activity. C, lysates were
subjected to Western blotting and probed as indicated. D, total RNA was prepared, and poly(A) RNA was isolated. Relative expression of aromatase was
quantified by real time PCR. The values were normalized to levels of -actin. E, tissue lysates were used tomeasure aromatase activity. In B,D, and E, means
S.D. (error bars) are shown, n 6. ***, p 0.001 compared with p53/mice.
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for the PGE2-mediated induction of aromatase (10), whereas
PGE2 also suppresses p53 in breast adipose stromal cells (16).
We also confirm that HIF-1 is a client protein of Hsp90 in LFS
stromal cells as silencing Aha1 or treatment with Hsp90 inhib-
itors suppressedHIF-1 protein levels. Our data support grow-
ing evidence that HIF-1 has roles that go beyond those of
mediating responses to hypoxia. The direct causal relationship
between the loss of p53 and increased expression ofHIF-1was
further supported by evidence that silencing p53 leads to an
increase inHIF-1 expression inwild-type stromal cells.More-
over, rescuing p53 in LFS-derived stromal cells led to inhibition
of HIF-1 levels.
PKM2 is a key mediator of theWarburg effect, the phenom-
enon by which proliferating cells alter their mode of energy
production from oxidative phosphorylation to aerobic glycoly-
sis, and its expression is increased in cancer cells (35, 36).
Although the metabolic function of PKM2 is well established,
our findings support a role for this protein as a regulator of gene
expression via direct interactions with HIF-1. Here, we show
that the tumor suppressor p53 is a regulator of PKM2 expres-
sion, providing a novel mechanism for the regulation of PKM2
in LFS-derived stromal cells. First, we show that PKM2 levels
are higher in LFS comparedwithwild-type stromal cells.More-
over, silencing p53 in wild-type cells enhanced the expression
of PKM2,whereas reactivation of p53 led to a decrease in PKM2
levels in LFS cells. In LFS patients, PKM2 was present in both
the cytosol and nucleus of adipose stromal cells. In contrast,
PKM2 was barely detectable in the nuclei of adipose stromal
cells fromwomenwithout LFS. The observation that PKM2can
be found in the nucleus of LFS adipose stromal cells is consis-
tent with recent findings demonstrating increased nuclear
localization of PKM2 in breast cancer patients (37). Next, we
show that p53 regulates PKM2 expression via Hsp90 and that
PKM2 is a client protein ofHsp90. To our knowledge, this is the
first study to report that PKM2 is a client protein of Hsp90.
Consistent with this, silencing Aha1 or treatment with Hsp90
inhibitors down-regulated PKM2 levels. Immunoprecipitating
Hsp90 co-precipitated PKM2, suggesting a complex between
Hsp90 and PKM2. The increased expression of PKM2 is causal
to the increased expression of aromatase observed in LFS-de-
rived stromal cells because it interacts directly with aromatase
PII and is required for the increased expression of aromatase in
LFS versus normal adipose stromal cells. Recently, PKM2 has
been shown to have a role in the nucleus as a transcriptional
regulator. In particular, it can co-activateHIF-1 andmodulate
expression of HIF-1 target genes (29–32). In LFS cells, we
show that PKM2andHIF-1 form a complex that is localized in
the nucleus. Previous findings had demonstrated that p53, via
binding to the aromatase promoter, suppressed basal levels of
aromatase (16). Our data suggest that p53 regulates aromatase
expression in a HIF-1 and PKM2-dependent manner (Fig. 9).
Consistent with our in vitro results, increasedHsp90ATPase
activity, HIF-1, PKM2, and aromatase expression were
observed in mammary tissues of p53 null compared with p53
wild-typemice. These results are consistent with previous find-
ings demonstrating that aromatase is elevated in p53-inacti-
vated mammary epithelial cells (17). In this previous study, the
increase in aromatase was attributed to effects on a known aro-
matase stimulator, CREB. Interestingly, HIF-1 has previously
been shown to act cooperatively with CREB to stimulate aro-
matase expression (27), suggesting that a larger complex con-
tainingHIF-1, PKM2, andCREBmay be required formaximal
induction of aromatase via this pathway.
LFS, despite being a rare disorder, also provides us with
potential new insights into the biology of sporadic breast can-
cers, of whichmore than 30% havemutations in p53 (38). Based
on the current results, we posit that processes that chronically
suppress levels of p53 or stimulate Hsp90 ATPase activity will
induce aromatase, thereby increasing the risk of hormone
receptor-positive breast cancer.
FIGURE 8. PKM2 is detectable in the nucleus of LFS stromal cells and is
positively correlated with HIF-1 and aromatase. PKM2, HIF-1, and aro-
matase immunoreactivity and localizationwere examined in adipose stromal
cells from normal breast tissue and breast tissue from LFS patients using
immunofluorescence and confocalmicroscopy. A, PKM2 (green) is detectable
in the cytoplasm of stromal cells from normal breast tissue (white arrows). In
LFS breast adipose stromal cells, PKM2 (B, C, and E; green) and HIF-1 (C; red)
are detectable in the cytoplasm and nucleus. Co-localization of PKM2 and
HIF-1 is visible in the nucleus of LFS stromal cells (C; white arrows), and the
relative fluorescence intensity for HIF-1 is positively correlated with nuclear
PKM2 (D). E, PKM2 (green) and aromatase (red) also co-localize in adipose
stromal cells from LFS (arrows). F, aromatase immunofluorescence staining is
positively correlated with nuclear PKM2 in these cells. Insets in A and B are
two-channel images where Hoescht nuclear staining is in blue and PKM2 in
green. Images presented (LFS6) are representative of samples examined (n
7/group). Scale bars in A and B represent 25 m. Arom, aromatase.
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Experimental Procedures
Materials—Glucose-6-phosphate, pepstatin, leupeptin, glu-
cose-6-phosphate dehydrogenase, zinc chloride, DMSO, L-lac-
tate dehydrogenase, G418, phosphoenolpyruvate, pyruvate
kinase, NADH, antibodies to -actin, and primers for PKM2
and -actin were purchased from Sigma. CP-31398 was pro-
vided by theNational Cancer InstituteChemopreventiveAgent
Repository. 17-Allylamino-17demethoxygeldanamycin (17-
AAG)was obtained fromCaymanChemicals. PU-H71was pur-
chased from Tocris Bioscience. Monoclonal aromatase anti-
body 677 was obtained from the Baylor College of Medicine
(39). Antibodies to PKM2 (Western blotting 1:1000; 4053, and
immunofluorescence) and HIF-1 (1:1000; D2U3T) were from
Cell Signaling Technology, whereas the HIF-1 antibody used
for immunofluorescencewas purchased fromBDTransduction
Laboratories. Antibodies to Hsp90 (1:500; SC-101494) and p53
(1:1000; SC6243) were from Santa Cruz. Antibody to Aha1 was
purchased from Abcam (1:1000; EPR13888). NE-PER nuclear
and cytoplasmic extraction kit, control siRNA and siRNAs to
Aha1, HIF-1, PKM2, and p53 were from Thermo Scientific. A
second set of siRNAs to GFP, p53, PKM2, and HIF-1 was
purchased from Qiagen. EpiTect ChIPone-day kits were pur-
chased from SA Bioscience. Western blotting detection re-
agents were from PerkinElmer Life Sciences. p53-luciferase
plasmid was from Panomics. Reagents for the luciferase assay
and pSVgal were from Promega. Aromatase promoter
(CYP19PII) was kindly provided by Dr. S. Chen (City of Hope,
Duarte, CA). 1-[3H]Androstenedione was from PerkinElmer
Life Sciences.
Cell Culture—Human mammary stromal cells HMS32-
hTERT (wild-type 53) and IUSM-LFS-HMS were provided by
Dr. Brittney-Shea Herbert (Indiana University School of Med-
icine) and grown as previously described (40, 41). The IUSM-
LFS-HMS cells express a heterozygous TP53 12141delG germ
line frameshift mutation (41). EB-1, a human colon carcinoma
cell line, was kindly provided byDr. Arnold J. Levine (Princeton
University) (24, 25). EB-1 cells were maintained in RPMI
mediumwith 10% FBS and supplementedwith 0.5 g/liter G418.
HCT116 cells (p53 wild-type and p53 null) were obtained from
Dr. Bert Vogelstein (42). These cells were grown inMcCoy’s 5A
medium supplemented with 10% FBS. Human preadipocytes
(adipose stromal cells) derived from subcutaneous fat and prea-
dipocyte growth medium were purchased from Cell Applica-
tions, Inc. Cellular cytotoxicity was assessed by measurements
of cell number, lactate dehydrogenase release, and 3-(4,5-dim-
ethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. No evidence of cell toxicity was detected in any of the
experiments described below (data not shown).
Co-immunoprecipitation—This assay was performed using a
catch and release reversible immunoprecipitation system from
Upstate Biotechnology. Cell lysate or tissue lysate (500–1000
g) proteinwas used for immunoprecipitation at room temper-
ature. The immunoprecipitates were then subjected to West-
ern blot analysis.
Western Blotting—Cells and tissues were lysed by suspending
in lysis buffer (150mMNaCl, 100mMTris, pH8.0, 1%Tween 20,
50 mM diethyldithiocarbamate, 1 mM EDTA, 1 mM phenyl-
methylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml trypsin
inhibitor, and 10 g/ml leupeptin) followed by sonication. Cell
and tissue protein extracts were clarified following centrifuga-
tion to remove particulate material. The protein concentration
was determined according to Lowry et al. (43). Mouse mam-
mary gland tissue lysateswere either subjected toWestern blot-
ting for Hsp90 and -actin or immunoprecipitated with anti-
sera to p53, PKM2, Aha1, and HIF-1 followed by Western
blotting. Lysates were subjected to SDS-PAGE under reducing
conditions on 10% polyacrylamide gels. Separated proteins
were transferred onto nitrocellulose sheets and incubated with
the indicated antisera followed by a secondary antibody to
FIGURE 9. Signaling pathway bywhich p53 regulates aromatase in LFS stromal cells. A, in stromal cells with wild-type p53, Aha1 is suppressed leading to
the decreased ATPase activity of Hsp90 and the decreased stabilization of HIF-1 and PKM2. B, mutation or loss of p53 leads to an increase in Aha1 expression,
which leads in turn to enhanced Hsp90 ATPase activity. This results in stabilization of HIF-1 and PKM2, their increased binding to the CYP19A1 promoter, and
the up-regulation of aromatase expression.
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horseradish peroxidase conjugated IgG. The blots were then
probed with the ECLWestern blot detection system.
Quantitative Real Time PCR—Total RNA was isolated from
cells using the RNeasy mini kit (Qiagen). For mammary gland
tissue analyses, poly(A) RNA was prepared with an Oligotex
mRNA mini kit (Qiagen). Poly(A) or total RNA was reversed
transcribed using murine leukemia virus reverse transcriptase
and oligo(dT)16 primer. The resulting cDNA was then used for
amplification. The primers for murine and human aromatase
have been described previously (5, 9, 44, 45). The primers for
PKM2were 5-GTCTGGAGAAACAGCCAAGG-3 (forward)
and 5-CGGAGTTCCTCGAATAGCTG-3 (reverse) (46).
-Actin was used as an endogenous normalization control;
primers were purchased fromQiagen. Real time PCR was done
using 2 SYBR green PCR master mix on a 7500 real time
PCR system (Applied Biosystems). Using the ddCT (relative
quantification) analysis protocol, relative fold induction was
determined.
Transient Transfections—The cells were grown to 60–70%
confluence in 6-well dishes. The cells were then transfected
using Lipofectamine 2000 (Invitrogen) for 24 h. Following trans-
fection, the medium was replaced with serum-free medium for
another 24 h. Luciferase and -galactosidase enzyme activities
were measured in cellular extracts. Luciferase activity in cell
lysates was normalized to -galactosidase enzymatic activity.
RNA Interference—The cells were transfected with 2 g of
siRNA oligonucleotides using DharmaFECT 4 transfection re-
agent according to the manufacturer’s instructions.
ChIP Assay—ChIP assay was performed using the EpiTect
ChIPone-day kit from SA Bioscience. Approximately, 4  106
cells were cross-linked in a 1% formaldehyde solution at 37 °C
for 10 min. Cross-linked cells were then lysed and sonicated to
generate 200–1000-bp DNA fragments. Cell lysates were sub-
jected to centrifugation, and the cleared supernatant was incu-
bated with 4 g of the PKM2 or HIF-1 antibodies at 4 °C
overnight. Immune complexes were precipitated, washed, and
eluted as described in the manufacturer’s protocol. DNA-pro-
tein cross-links were reversed by heating at 65 °C for 4 h, and
the DNA fragments were purified and used as a template for
PCR amplification. Quantitative real time PCRwas carried out.
For ChIP analysis, the CYP19A1 oligonucleotide sequences for
PCR primers were 5-AACCTGATGAAGTCACAA-3 (for-
ward) and 5-TCAGACATTTAGGCAAGACT-3 (reverse).
This primer set covers the CYP19A1 promoter I.3/II segment
from nucleotide302 to38.PCR was performed at 94 °C for
30 s, 62 °C for 30 s, and 72 °C for 45 s for 35 cycles, and real time
PCR was performed at 95 °C for 15 s and 60 °C for 60 s for 40
cycles. The PCRproduct generated from theChIP templatewas
sequenced, and the identity of the CYP19A1 promoter was
confirmed.
Aromatase Activity—Aromatase activity assay was based on
measurement of tritiated water released from 1-[3H]andro-
stenedione (5, 9, 18, 44, 45). The reaction was also done in the
presence of letrozole, a specific aromatase inhibitor, as well as a
specificity control and without NADPH as a background control.
Aromatase activity was normalized to protein concentration.
Hsp90 ATPase Activity—The ATPase assay was based on a
regenerating coupled enzyme assay and was performed as
described earlier (21, 22, 47). Hsp90 ATPase activity is
expressed as pmol/min/mg protein.
Animal Model—p53 knock-out mice carrying the Trp53tm1Tyj
allele were maintained on the 129S6 inbred strain background.
Genotyping was performed by PCR analysis of DNA extracted
from tail tip biopsies (48). Tissues were harvested from female
p53/ and p53/ littermate control mice at 6–10 weeks of
age. Mammary gland tissue was isolated and rinsed once with
PBS and then snap frozen for subsequent molecular analysis.
All animal use was performed in accordance with federal and
institutional guidelines, under a protocol approved by the Cor-
nell University Institutional Animal Care and Use Committee.
Immunofluorescence and Confocal Microscopy—Breast tis-
sue fromLFSpatientswas obtained fromkConFab (Melbourne,
Australia) and comparedwith normal breast tissue from reduc-
tion mammoplasty from women of similar ages. The studies
have been approved byMonashHealthHumanResearch Ethics
Committee B and the Peter MacCallum Cancer Centre. LFS
patient details are included in Table 1. Formalin-fixed paraffin-
embedded sections from normal breast tissue and LFS patients
were dewaxedwith xylene and rehydrated in descending grades
of ethanol. Immunofluorescence was performed after antigen
retrieval in 100 °Cwater bathwith 10mMTris, 1mMEDTAbuffer
for 30 min. Sections were then washed in PBS and blocked with
0.5% BSA/PBS for 30min. Primary antibodies (1:200 rabbit mAb
PKM2 4053P from Cell Signaling Technology and 1:100 mouse
mAb HIF-1, 610958 from BD Transduction Laboratories and
1:500 mouse mAb Aromatase #677 (Dean Edwards, Baylor Col-
lege of Medicine, Houston, TX)) were diluted in PBS and incu-
bated overnight at 4 °C followed by the application of 1:750 of
anti-mouseAlexaFluor546,1:750anti-rabbitAlexaFluor488, and
1:2000Hoechst 33342 (Invitrogen) for 2 h. The sectionswere then
TABLE 1
Li-Fraumeni Syndrome sample characteristics




1 62 g.14069 C	T (R248W) ER, PR, HER2 0.7969b 0.6525b
2 40 dup exons 2_6 ER, PR, HER2 0.5715b 0.8178b
3 45 c.215C	G (P72R)c ER, PR, HER2 0.8331b 0.7175b
4 49 c.215C	G (P72R) ER, PR, HER2 0.7244b 0.4079b
5 33 c.524 G	A (R175H) ER, N/A, HER2 0.7187b 0.7312b
6 43 c.393_395
CAA (N131
) ER, PR, HER2 0.7537b 0.6623b
7 27 c.584 T	C, c.215 C	G ER, PR, HER2 0.9259b 0.6092b
a Age (in years) at time tissue was obtained.
b p 0.0001.
c BRCA2 mutation carrier.
p53 Regulates Aromatase Expression via HIF-1/PKM2 Axis
JULY 29, 2016•VOLUME 291•NUMBER 31 JOURNAL OF BIOLOGICAL CHEMISTRY 16021
washed and mounted with ProLong Gold antifade mountant
(P36934 from Thermo Fisher Scientific). Imaging was done using
the Nikon inverted confocal microscope.
Statistics—Comparisons between groups were made by
Student’s t test. A difference between groups of p  0.05 was
considered significant. For correlation studies, the Pearson cor-
relation coefficient r was calculated from n  100 cells using
GraphPad Prism 6.
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